Annalisa Talami
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Annalisa Talami has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Alessandro Pulsoni
Division of Hematology, Department of Translational and Precision Medicine, S.M. Goretti Hospital Sapienza University—Polo Pontino Latina Italy
2 shared publications - Andrés José Maria Ferreri
Strategic Program on Lymphomas IRCCS San Raffaele Scientific Institute, Milano and Vita‐Salute San Raffaele University Milan Italy
2 shared publications - Elsa Pennese
UOC Ematologia Presidio Ospedaliero Pescara Pescara Italy
2 shared publications - Emanuele Cencini
Unit of Hematology, Azienda Ospedaliera Universitaria Senese, University of Siena, 53100 Siena, Italy
2 shared publications - Guilherme Duffles
Hematology and Hemotherapy Centre, University of Campinas Sao Paulo Brazil
2 shared publications - Luca Arcaini
Department of Molecular Medicine University of Pavia Pavia Italy
2 shared publications
Latest Publications
- Open Access
- 30 August 2026
- Published by Wiley in British Journal of Haematology
- Vol. 209 (5) , 2066-2072
Survival after first relapse in marginal zone lymphomas: Prospective data from the international observational NF10 study
Summary: While marginal zone lymphoma (MZL) is generally indolent, outcomes following relapse remain poorly defined. This study utilized the indolent Non Follicular 10 (NF10) prospective database to characterize survival and identify prognostic drivers in patients failing initial systemic therapy. The study analysed 122 patients with relapsed MZL. The primary end‐point was progression‐free survival from first relapse (2PFS), with survival after relapse (SAR) as the secondary end‐point. The median 2PFS was 24 months, with a 2‐year 2PFS rate of 49% and a 2‐year SAR rate of 66%. Multivariable analysis identified advanced age, progression of disease within 24 months (POD24) and high MZL International Prognostic Index (MZL‐IPI) scores as significant predictors of inferior survival. Patients with splenic and disseminated subtypes also demonstrated worse outcomes. Relapse following systemic therapy often marks a transition to an aggressive clinical course. Time to progression and the MZL‐IPI are robust tools for risk stratification, highlighting an urgent need for novel therapeutic strategies for high‐risk relapsed MZL populations.
- 30 August 2026
- Published by Wiley in British Journal of Haematology
- Vol. 209 (5) , 2066-2072
Open AccessSurvival after first relapse in marginal zone lymphomas: Prospective data from the international observational NF10 study
Summary: While marginal zone lymphoma (MZL) is generally indolent, outcomes following relapse remain poorly defined. This study utilized the indolent Non Follicular 10 (NF10) prospective database to characterize survival and identify prognostic drivers in patients failing initial systemic therapy. The study analysed 122 patients with relapsed MZL. The primary end‐point was progression‐free survival from first relapse (2PFS), with survival after relapse (SAR) as the secondary end‐point. The median 2PFS was 24 months, with a 2‐year 2PFS rate of 49% and a 2‐year SAR rate of 66%. Multivariable analysis identified advanced age, progression of disease within 24 months (POD24) and high MZL International Prognostic Index (MZL‐IPI) scores as significant predictors of inferior survival. Patients with splenic and disseminated subtypes also demonstrated worse outcomes. Relapse following systemic therapy often marks a transition to an aggressive clinical course. Time to progression and the MZL‐IPI are robust tools for risk stratification, highlighting an urgent need for novel therapeutic strategies for high‐risk relapsed MZL populations.
- Open Access
- 29 March 2026
- Published by Wiley in British Journal of Haematology
- Vol. 208 (6) , 2229-2234
Hepatitis C virus and hepatitis B virus in indolent lymphomas: Prospective data from the international observational NF10 study
- 29 March 2026
- Published by Wiley in British Journal of Haematology
- Vol. 208 (6) , 2229-2234
Open AccessHepatitis C virus and hepatitis B virus in indolent lymphomas: Prospective data from the international observational NF10 study